导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.77% | 774/4345 |
| 近一周 | -1.17% | 1580/4962 |
| 近一月 | -3.20% | 2078/4922 |
| 近一季 | -3.62% | 1533/4747 |
| 近半年 | 1.60% | 1053/4477 |
| 近一年 | 14.50% | 755/4016 |
| 近两年 | 83.26% | 737/2712 |
| 近三年 | 52.46% | 473/2054 |
| 成立以来 | 145.85% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.70% 1212/4961 |
16.16% 1593/5312 |
- - |
- - |
| 2025 | 32.18% 1195/4813 |
4.09% 995/3635 |
3.09% 1172/4076 |
21.17% 1838/4524 |
1.65% 1279/4813 |
| 2024 | 9.60% 1458/3463 |
-1.04% 1173/2808 |
-3.43% 1371/3014 |
15.50% 1699/3129 |
-0.71% 1500/3463 |
| 2023 | -6.22% 823/2656 |
5.51% 780/2280 |
-2.86% 692/2385 |
-4.73% 1210/2515 |
-3.96% 829/2655 |
| 2022 | -18.44% 709/2207 |
-9.81% 351/1919 |
3.16% 1203/2016 |
-11.88% 602/2113 |
-0.53% 1620/2208 |
| 2021 | 25.30% 111/1822 |
1.58% 249/1255 |
14.15% 267/1330 |
7.01% 199/1466 |
0.98% 1029/1822 |
| 2020 | 42.58% 262/1250 |
-1.92% 248/1028 |
18.91% 319/1067 |
17.14% 115/1164 |
4.37% 847/1184 |
| 2019 | - - |
- - |
-5.83% 482/788 |
7.35% 92/850 |
7.77% 399/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国投瑞银中证500指数量化增强C VS. 长安沪深300非周期A(740101) |